Key Takeaway: Cognition Therapeutics, led by CEO Lisa Ricciardi, shared positive outcomes from their phase 2 clinical trial of zervimesine for dementia with Lewy bodies during a Benzinga interview. The results indicate potential advancements in treating this critical form of dementia. The interview highlights the company's commitment to addressing this serious condition.
Price reaction · baseline $0.7693 (2025-01-22 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
POSITIVE FACTORS
Positive results from phase 2 clinical trial of zervimesine.
Targeting a critical form of dementia with a specific treatment.
CEO Lisa Ricciardi's insights on the company's progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Cognition Therapeutics is Targeting a Critical Form of Dementia
Lisa Ricciardi, president and CEO of Cognition Therapeutics (CGTX) was a guest on Benzinga’s All-Access on January 7, 2025. During the interview, she discussed the positive results from the company’s phase 2 clinical trial of zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB). Watch the full interview here:
share this video
Frequently Asked Questions
What is zervimesine?
Zervimesine (CT1812) is a treatment being tested for dementia with Lewy bodies.
What were the results of the phase 2 trial?
The phase 2 clinical trial of zervimesine showed positive results in patients.
Who is the CEO of Cognition Therapeutics?
Lisa Ricciardi is the president and CEO of Cognition Therapeutics.